| Naslov: | Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria : results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial |
|---|
| Avtorji: | ID Giżewska, Maria (Avtor)
ID Inwood, Anita (Avtor)
ID Tyčová, Renáta (Avtor)
ID Vijay, Suresh (Avtor)
ID Fjellbirkeland, Olivia (Avtor)
ID Grošelj, Urh (Avtor), et al. |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,25 MB)
MD5: 8FD0CABD7704820A090B35DC1722B120
 URL - Izvorni URL, za dostop obiščite https://www.metabolismjournal.com/article/S0026-0495(26)00022-3/fulltext
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Aim: AMPLIPHY is the first Phase 3 study comparing sepiapterin versus sapropterin in children and adults with phenylketonuria (PKU). Methods: AMPLIPHY was an international, Phase 3, two-part, open-label study in participants with PKU aged ≥2 years. Participants responsive to sepiapterin (60 mg/kg/day) in Part 1 (≥20% reduction in blood phenylalanine [Phe]) entered Part 2, a crossover treatment period, and were randomized 1:1 to alternative treatment sequences of sepiapterin (60 mg/kg/day, licensed dosage) and sapropterin (20 mg/kg/day, maximum licensed dosage) for 4 weeks each, with a 14-day washout between treatments. The primary endpoint was mean change in blood Phe from baseline to Weeks 3-4 of each treatment period (Part 2). Results: Of 82 participants enrolled, 67 (81.7%) and 62 (75.6%) had reductions in blood Phe ≥20% and ≥ 30%, respectively, in Part 1. Sixty-two participants were randomized in Part 2 (mean [SD] age, 15.8 [10.8] years). In the primary analysis set (≥30% reduction in blood Phe in Part 1, n = 58), mean (SD) baseline blood Phe before sepiapterin and sapropterin treatment was 725.8 (302.1) and 790.4 (370.0) μmol/L, respectively. Least-squares mean (SE) reduction in blood Phe from baseline was -437.0 (28.0) and - 256.6 (28.2) μmol/L, respectively, representing a least-squares mean difference of -180.4 μmol/L (95% CI: -229.5, -131.4; p < 0.0001) and a relative 70% greater reduction with sepiapterin versus sapropterin. Both treatments were well tolerated, with safety profiles consistent with previous reports. Conclusions: Sepiapterin was superior to the highest approved dose of sapropterin in lowering blood Phe. No new safety signals were observed. |
|---|
| Ključne besede: | AMPLIPHY, efficacy, PKU, phenylketonuria, phenylalanine, safety, sapropterin, sepiapterin |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | str. 1-10 |
|---|
| Številčenje: | Vol. 178, [article no.] 156513 |
|---|
| PID: | 20.500.12556/DiRROS-28316  |
|---|
| UDK: | 616 |
|---|
| ISSN pri članku: | 1532-8600 |
|---|
| DOI: | 10.1016/j.metabol.2026.156513 |
|---|
| COBISS.SI-ID: | 267796995 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis z dne 9. 2. 2026;
|
|---|
| Datum objave v DiRROS: | 13.03.2026 |
|---|
| Število ogledov: | 16 |
|---|
| Število prenosov: | 13 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
